Shares of VectivBio Holding AG (VECT) are down 88% from their all-time high of $37.70, recorded last April, and trade around $5.
Switzerland-based VectivBio is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. The lead drug candidate is Apraglutide, a next-generation GLP-2 analog, which according to the company represents a potential "pipeline in a product" opportunity.
Apraglutide is under the following trials:
-- A phase III study in adult patients with short bowel syndrome with intestinal failure, dubbed STARS.
Short bowel syndrome with intestinal failure (SBS-IF) is a highly disabling condition caused by severe intestinal loss induced by surgery, trauma, or infarction, and less usually by a congenital abnormality or a reduction in absorptive surface as a result of diffuse disease. (Source: American Gastroenterological Association)
-- A phase II metabolic balance study in colon-in-continuity (CIC) patients with short bowel syndrome with intestinal failure, dubbed STARS Nutrition.
-- A phase II trial in patients with steroid-refractory gastrointestinal acute Graft versus Host Disease, dubbed STARGAZE.
Anticipated Milestones:
-- Topline results from the STARS trial of Apraglutide in short bowel syndrome with intestinal failure are expected by the end of 2023.
-- Interim data from the STARS Nutrition trial is expected to be presented at a scientific conference in the second half of this year.
-- Interim data from the STARGAZE trial of Apraglutide in acute Graft versus Host Disease is expected in the first half of 2023.
Also in the pipeline are a couple of compounds in early stage of research/development like VB-1197, VB-1200, VB-1300, and VB-1400.
VB-1197, being developed for the treatment of methylmalonic acidemia and propionic academia, is under preclinical development. The company plans to initiate a first-in-human trial of VB-1197 in the second half of 2023.
Methylmalonic acidemia and Propionic academia are rare, autosomal recessive disorders of amino acid metabolism.
The other compounds are in research stage.
Licensing Agreements & Deals:
Last month, VectivBio entered into an exclusive licensing agreement with Asahi Kasei Pharma Corp. to develop and commercialize Apraglutide in Japan. The company has also established a loan facility with Kreos Capital, a global growth lender to life sciences and healthcare companies, to access up to $75 million, with a minimum commitment to draw down $10 million.
Cash position:
Cash and cash equivalents totaled $102.7 million at December 31, 2021. The license deal and loan facility agreement provides the company up to $117 million.
Vectiv's shares began trading on the Nasdaq Global Select Market on April 9, 2021, pricing its shares at $17 each. The stock opened that day at $22.82, touched an intraday high of $37.70, and closed at $24.23.
VECT has thus far hit a low of $2.74 and a high of $37.70. The stock closed Friday's trading at $5.00, unchanged from the previous day's close.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.